Taro Inks $36M Investor Deal Over Generics Price-Fixing

By Lauren Berg

Taro Pharmaceutical Industries shareholders asked a New York federal judge Monday to greenlight a $36 million settlement resolving proposed class claims that the company misled investors about alleged generic drug price-fixing that led to a drop in stock price upon news of a U.S. Department of Justice antitrust investigation.

 Motion attached | Read full article » | Save to favorites »